← Search & browse all drugs

tagraxofusp

L01XX67

Forms & Strengths

Intravenous solution: 1 mcg/mL in a single-dose vial

Adult Dosing

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): 12 mcg/kg IV once daily on days 1-5 of a 21-day cycle
Premedication: Administer an antihistamine, corticosteroid, and antipyretic 30-60 minutes prior to each infusion

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established

Indications

Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in untreated and previously treated adult and pediatric patients aged 2 years and older

Mechanism of Action

CD123-directed cytotoxin consisting of interleukin-3 (IL-3) fused to truncated diphtheria toxin, which binds to CD123 on target cells, internalizes, and inhibits protein synthesis leading to cell death

Contraindications

None

Adverse Reactions

Capillary leak syndrome (can be fatal)
Hypoalbuminemia
Peripheral edema
Weight increased
Fatigue
Nausea
Pyrexia
Elevated transaminases

Drug Interactions

Avoid co-administration with strong CYP3A inhibitors/inducers if metabolism is affected, though pharmacokinetic interactions are primarily managed via monitoring
Caution with hepatotoxic drugs due to risk of increased liver enzymes and transaminitis

Curated Content: Needs Vetting Before Put to Clinical Use